OPKO Health, Inc.SEC Filings
|
|
All SEC filings by OPKO Health, Inc. (OPK) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q/A | Quarterly report | View Diff | Aug 28, 2026 | |
| 10-Q/A | Quarterly report | View Diff | Aug 28, 2026 | |
| 10-Q | Quarterly report | View Diff | Jul 27, 2026 | |
| ARS | Annual report to shareholders | Apr 30, 2026 | ||
| 10-Q | Quarterly report | View Diff | Apr 28, 2026 | |
| 10-K | Annual report | View Diff | Feb 26, 2026 | |
| 10-Q | Quarterly report | View Diff | Oct 29, 2025 | |
| 10-Q | Quarterly report | View Diff | Jul 31, 2025 | |
| 10-Q | Quarterly report | View Diff | May 1, 2025 | |
| 10-K/A | Annual report | View Diff | Mar 21, 2025 |
Events
| 8-K | Current report | Aug 14, 2026 | ||
| 8-K | Opko Health Reports Second Quarter 2026 Business Highlights and Financial Results | Jul 27, 2026 | ||
| 8-K | Current report | Jun 18, 2026 | ||
| 8-K | Opko Health Reports First Quarter 2026 Business Highlights and Financial Results | Apr 28, 2026 | ||
| 8-K | Departure of Directors or Certain Officers | Mar 19, 2026 | ||
| 8-K | Opko Health Reports Fourth Quarter 2025 Business Highlights and Financial Results | Feb 26, 2026 | ||
| 8-K | Opko Health Reports Third Quarter 2025 Business Highlights and Financial Results | Oct 29, 2025 | ||
| 8-K | Labcorp Completes Acquisition of Select Assets of Bioreference Health'S Innovative Oncology and Related Clinical Testing Services Businesses | Sep 15, 2025 | ||
| 8-K | Opko Health Reports Second Quarter 2025 Business Highlights and Financial Results | Jul 31, 2025 | ||
| 8-K | Departure of Directors or Certain Officers | May 29, 2025 |
Registrations and Prospectuses
| S-8 | Registration of securities for employees | May 15, 2023 | ||
| 424B5 | Prospectus supplement for primary offering | Oct 25, 2019 | ||
| 424B5 | Prospectus supplement for primary offering | Oct 24, 2019 | ||
| 424B5 | Prospectus supplement for primary offering | Oct 22, 2019 | ||
| 424B2 | Prospectus for primary offering | Feb 6, 2019 | ||
| 424B7 | Prospectus with selling stockholder info | Feb 5, 2019 | ||
| FWP | Free writing prospectus | Feb 5, 2019 | ||
| 424B5 | Prospectus supplement for primary offering | Feb 4, 2019 | ||
| S-3ASR | Automatic shelf registration | Jan 28, 2019 | ||
| 25 | Voluntary exchange delisting | Jun 23, 2016 |
Proxies
| DEFA14A | Additional proxy soliciting materials | May 15, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 30, 2026 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 30, 2026 | |
| DEFA14A | Additional proxy soliciting materials | Mar 14, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Mar 14, 2025 | |
| DEFR14A | Revised proxy | Aug 30, 2024 | ||
| DEF 14A | Definitive proxy | View Diff | Feb 29, 2024 | |
| PRE 14A | Preliminary proxy | Feb 16, 2024 | ||
| DEFA14A | Additional proxy soliciting materials | May 17, 2023 | ||
| DEFA14A | Additional proxy soliciting materials | May 1, 2023 |
Other
| UPLOAD | Letter from SEC | Dec 26, 2018 | ||
| CORRESP | Correspondence with SEC | Dec 4, 2018 | ||
| UPLOAD | Letter from SEC | Nov 19, 2018 | ||
| CORRESP | Correspondence with SEC | Oct 11, 2018 | ||
| CORRESP | Correspondence with SEC | Oct 5, 2018 | ||
| UPLOAD | Letter from SEC | Sep 13, 2018 | ||
| CORRESP | Correspondence with SEC | Aug 17, 2018 | ||
| UPLOAD | Letter from SEC | Aug 3, 2018 | ||
| CT ORDER | Confidential treatment order | Apr 12, 2018 | ||
| UPLOAD | Letter from SEC | Oct 19, 2017 |
Ownership
| SC 13D | Beneficial ownership report | Aug 7, 2026 | ||
| 4 | Logal Adam | Jul 28, 2026 | ||
| 4 | Rubin Steven D | Jul 28, 2026 | ||
| SC 13D/A | Beneficial ownership report | Jul 1, 2026 | ||
| 4 | Lachman Prem A | Jun 22, 2026 | ||
| 4 | Medel Roger Md | Jun 22, 2026 | ||
| 4 | Paganelli John A | Jun 22, 2026 | ||
| 4 | Pfenniger Richard C Jr | Jun 22, 2026 | ||
| 4 | Uppaluri Subbarao V | Jun 22, 2026 | ||
| 4 | Yu Alice Lin-Tsing | Jun 22, 2026 |